Cancilico, a Dresden-based AI diagnostics company focused on blood cancer, has raised €2.5M in seed funding to accelerate the rollout of its software platform for bone marrow analysis. The company aims to make AI-supported diagnostics a routine part of hematology workflows worldwide.